header logo image


Page 14«..10..13141516..2030..»

Archive for the ‘Genetics’ Category

Genetic detectives begin work to trace spread of COVID-19 in Canada – The Globe and Mail

Sunday, July 12th, 2020

For the last four months, Canadas public health experts have been racing to stop the spread of COVID-19 by trying to figure out how everyone is getting it, and whom they may have given it to.

But even the best efforts have left doctors stymied about the source of more than one-third of this countrys known COVID-19 infections. Not knowing where cases come from makes outbreaks that much harder to stamp out.

Now medical researchers and supercomputers are turning genetics labs into virus detective agencies, looking first to find the novel coronavirus itself within blood samples from thousands of infected patients, and then comparing all of those isolated viruses to each other looking for places they differ.

Story continues below advertisement

Every close match will draw a line from patient to patient, ultimately painting a picture of how the virus spread.

This is the big effort over the next four weeks, said Andrew McArthur, director of the biomedical discovery and commercialization program at McMaster University.

Whats going to come out of there pretty soon is a glimpse of what just happened, how did it move around the province, how did it move between provinces or how big was Pearson (airport) in the early days of the airport being open.

Knowing how the virus spread will show where there were weaknesses in public health measures early on, said McArthur. Being able to keep divining genetic codes from samples will mean when there are flare-ups of cases, they can be quickly compared to each other to see if theyre all related or are coming from multiple sources.

It means, for example, a long-term care centre should be able to quickly know if its 10 new cases are because one case spread widely or arose from multiple carriers coming into the facility.

Thats a very different infection-control problem, said McArthur.

It also means that maybe, just maybe, the second COVID-19 wave most think is coming wont be as bad, or as hard to control, as the first, because the sources can be isolated very quickly.

Story continues below advertisement

A second wave is likely, McArthur said. But weve never spent this kind of money and effort before, either, so maybe well beat it.

The kinds of genetic technology being used for this project did not exist when SARS hit Canada in 2003.

This genetic mapping is constantly on the lookout for mutations. Thus far, SARS-CoV-2, the official name for the virus that causes COVID-19, has not mutated as quickly as many others do. Influenza, for instance, changes so much over a year the vaccine has to be retooled every summer to keep up.

But there are enough subtle changes still happening among the 28,000 individual markers that make up a genome for SARS-CoV-2 that cases can be traced backward and linked to the ones that came before. McArthur said it takes a lot of data storage, a lot of high-capacity computer analysis, and a lot of money, to run the comparisons among them all.

The federal government put $40 million on the table in April for genetic research on COVID-19. Half is to keep tabs on the virus as it spreads, look for any changes it undergoes, and map its pathway across the country. The other half is to look at the genetic structures of the patients who get infected, trying to answer the puzzling question of why some people die and others have symptoms so mild they never even know they are sick.

Genome Canada is administering the project, with six regional genomics agencies overseeing the work locally and labs like McArthurs doing the testing and analysis. The funding is intended to create genetic maps from 150,000 patients. Canada thus far has had about 108,000 positive cases, and the expectation is that almost every one of them will be gene-mapped.

Story continues below advertisement

The results will be loaded into a global site comparing all known infections of COVID-19, but also be analyzed for national and regional reports.

In New York, genetic sequencing was used to figure out that COVID-19 in Manhattan wasnt coming from China and Iran as imagined, but from Europe. In Canada, it is suspected that much of the virus came into this country from travellers returning from the United States in early March. But the work is only now beginning to confirm that belief.

McArthur estimates the first data will be available for Ontario in about four weeks, but warns it will take many more months to complete all of the tests. His lab sequenced 600 samples on Wednesday alone.

Overall, McArthur expects the genetics project to last for two years.

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the days most important headlines. Sign up today.

Read more from the original source:
Genetic detectives begin work to trace spread of COVID-19 in Canada - The Globe and Mail

Read More...

Global Genetic Modification Therapies Market Report 2020 Pandemic Situation to Boost Growth Top companies 4D Molecular Therapeutics, Abeona…

Sunday, July 12th, 2020

Global Genetic Modification Therapies Market analysis 2015-2027, is a research report that has been compiled by studying and understanding all the factors that impact the market in a positive as well as negative manner. Some of the prime factors taken into consideration are: various rudiments driving the market, future opportunities, restraints, regional analysis, various types & applications, Covid-19 impact analysis and key market players of the Genetic Modification Therapies market. nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

Download Report from: https://cognitivemarketresearch.com/medical-devicesconsumables/genetic-modification-therapies-market-report

Global Genetic Modification Therapies Market: Product analysis: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies, Gene Editing

Global Genetic Modification Therapies Market: Application analysis: Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations, Others

Major Market Players with an in-depth analysis: 4D Molecular Therapeutics, Abeona Therapeutics, Allergan, American Gene Technologies, Merck Millipore, AbbVie

The research is presented in such a way that it consists of all the graphical representations, pie charts and various other diagrammatic representations of all the factors that are used for the research. Genetic Modification Therapies market research report also provides information on how the industry is anticipated to provide a highly competitive analysis globally, revenues generated by the industry and increased competitiveness and expansions among various market players/companies.

Get A Free Sample of Genetic Modification Therapies Market Report: https://cognitivemarketresearch.com/medical-devicesconsumables/genetic-modification-therapies-market-report#download_report

The Genetic Modification Therapies industry is projected in assembling information regarding dynamic approximations and also listings of a profitable progression rate annually in the expected duration according to a recent & latest study. The latest Coronavirus pandemic impact along with graphical presentations and recovery analysis is included in the Genetic Modification Therapies research report. The research report also consists of all the latest innovations, technologies and systems implemented in the Genetic Modification Therapies industries.

Various factors with all the necessary limitations, expenditure/cost figures, consumer behaviour, supply chain, government policies and all the information related to the market have been included in the Genetic Modification Therapies Market report. The research report also provides light on various companies & their competitors, market size & share, revenue, forecast analysis and all the information regarding the Genetic Modification Therapies Market.

Checkout Inquiry for Buying or Customization of Report: https://cognitivemarketresearch.com/medical-devicesconsumables/genetic-modification-therapies-market-report#download_report.

Genetic Modification Therapies Market research report provides an in-depth analysis of the entire market scenario starting from the basics which is the market introduction till the industry functioning and its position in the market as well as all the projects and latest introductions & implementations of various products. The research study has been assembled by understanding and combining various analysis of regions globally & companies and all necessary graphs and tables that bring the theory into an exact representation through numerical values and standard tables.

The global estimations of the market value, market information/definition, classifications of all the types & applications, overall threats & dips that can be assumed and many other factors which consist the overall market scenario and its happening globally along with the forthcoming years are compiled in the Genetic Modification Therapies market research report. Hence this report can serve as a handbook/model for the enterprises/players interested in the Genetic Modification Therapies Market as it consists all the information regarding the Genetic Modification Therapies market.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Genetic Modification Therapies Market Report 2020 (Coronavirus Impact Analysis on Genetic Modification Therapies Market)

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.(*If you have any special requirements, please let us know and we will offer you the report as you want.)

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.Contact Us: +1-312-376-8303Email: nicolas.shaw@cognitivemarketresearch.comWeb: https://www.cognitivemarketresearch.com/

**********Download the Entire Report*************************************************https://cognitivemarketresearch.com/medical-devicesconsumables/genetic-modification-therapies-market-report

Continue reading here:
Global Genetic Modification Therapies Market Report 2020 Pandemic Situation to Boost Growth Top companies 4D Molecular Therapeutics, Abeona...

Read More...

Direct-To-Consumer (DTC) Genetic Testing- Global Market will Massively Expand during the period of 2020-2025 – 3rd Watch News

Sunday, July 12th, 2020

Market Research Exploreoffers an exhaustive analysis on the Global Direct-To-Consumer (DTC) Genetic Testing Market covering diverse significant factors that pose an impact on the current and forthcoming market conditions. The report elaborates on how the Direct-To-Consumer (DTC) Genetic Testing market has been performing over the last five years at the global and regional levels. It also analyzes expected ups and downs in the market over the next five years. The report assists market players to operate their business wisely. Market scope, establishment, profitability, maturity, and growth prospects are also highlighted in the global Direct-To-Consumer (DTC) Genetic Testing market report.

The report mainly emphasizes the market rivalry landscape, leading players profiles, segmentation, and industry environments which have been playing an integral role in posing impacts on market structure and profitability. It also includes a precise assessment of market share, size, demand, production, sales, and revenue that help intuit the financial health of the industry. It also illuminates various market dynamics such as changing product values, demand-supply variations, contemporary trends, pricing fluctuations, growth-driving forces, and unstable market conditions.

Sample Copy Global Direct-To-Consumer (DTC) Genetic Testing Market Report 2020:https://www.marketresearchexplore.com/report/global-direct-to-consumer-dtc-genetic-testing-industry-market-research-report/173811#enquiry

Extensive study of crucial Direct-To-Consumer (DTC) Genetic Testing market segments:

The global Direct-To-Consumer (DTC) Genetic Testing market has been segmented into a number of various vital segments such as types, applications, and regions. The report evaluates each segment at a minute level in view of its growth prospects, global demand, and current revenue. It also focuses on the segments that are exhibiting exponential growth during the year and help market players in selecting more profitable segments for their Direct-To-Consumer (DTC) Genetic Testing businesses and precisely determine the actual needs and wants of their customer base.

Global Direct-To-Consumer (DTC) Genetic Testing Market Competitive Assessment:

Expansive survey of Global Direct-To-Consumer (DTC) Genetic Testing Market 2020

According to the report findings, the global Direct-To-Consumer (DTC) Genetic Testing market report is extremely competitive and encouraging leading manufacturers and companies to execute various business and marketing strategies such as M&A activities, brand promotions, product launches, partnerships, and other expansions to perform comfortably in the relentless competition. The report further examines highlights new product developments, innovations, and technology adoptions done by the competitors in order to offer upgraded products and services in the global Direct-To-Consumer (DTC) Genetic Testing market.

The report also provides a detailed financial assessment of leading market vendors and insights into the competencies and capacities of these companies to assist Direct-To-Consumer (DTC) Genetic Testing market players for business expansions. The report also deeply analyzes effective product lines offered by various manufacturers and helps other participants to boost the quality of their products. Analysis based on forthcoming challenges and opportunities is also highlighted in the report, which will help Direct-To-Consumer (DTC) Genetic Testing market players build lucrative strategies and grab all growth opportunities.

Significant Features of the Global Direct-To-Consumer (DTC) Genetic Testing Market Report:

Connect with our industry experts at[emailprotected].

Read more:
Direct-To-Consumer (DTC) Genetic Testing- Global Market will Massively Expand during the period of 2020-2025 - 3rd Watch News

Read More...

Genetic Leukemia Detection Testing Market Evenly Poised To Reach A Market Value Of US$ By 2018 2028 – 3rd Watch News

Saturday, July 11th, 2020

Global Genetic Leukemia Detection Testing market size will reach xx million US$ by 2025, from xx million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and 2019-2025 as the forecast period to estimate the market size for Genetic Leukemia Detection Testing .

This industry study presents the global Genetic Leukemia Detection Testing market size, historical breakdown data (2014-2019) and forecast (2019-2025). The Private Plane production, revenue and market share by manufacturers, key regions and type; The consumption of Genetic Leukemia Detection Testing market in volume terms are also provided for major countries (or regions), and for each application and product at the global level.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-6733

Global Genetic Leukemia Detection Testing market report coverage:

The Genetic Leukemia Detection Testing market report covers extensive analysis of the market scope, structure, potential, fluctuations, and financial impacts. The report also enfolds the precise evaluation of market size, share, product & sales volume, revenue, and growth rate. It also includes authentic and trustworthy estimations considering these terms.

The Genetic Leukemia Detection Testing market has been reporting substantial growth rates with considerable CAGR for the last couple of decades. According to the report, the market is expected to grow more vigorously during the forecast period and it can also influence the global economic structure with a higher revenue share. The market also holds the potential to impact its peers and parent market as the growth rate of the market is being accelerated by increasing disposable incomes, growing product demand, changing consumption technologies, innovative products, and raw material affluence.

The following manufacturers are covered in this Genetic Leukemia Detection Testing market report:

Key Players

Examples of some of the key players identified in the genetic leukemia detection testing market are Thermofisher Scientific, Creative Diagnostics, Vector Labs, TCS Biosciences Ltd., Alchem Diagnostics, Vela Diagnostics, Beckman Coulter, ELItechGroup.

Market Segmentation

By Test Type

By Product

By End User

By Region

Key Data Points Covered in the Report

The report covers exhaustive analysis on:

Report Highlights:

Research Methodology

The market sizing of genetic testing leukemia kits will be done by adoption data triangulation approach. Demand-side approach will be followed to assess the actual market size of genetic testing leukemia kits. Secondary research will be done at the initial phase to identify the feasibility of the target products/technology categories and its respective segments, product and service offerings, in end-use facilities, adoption rate and future impact of new technologies. Additionally, per capita consumption of syringes, among end users will be tracked at a granular level to obtain the most accurate information. Each piece of information will be eventually analyzed during the entire research project, which helps build a strong base for the primary research information.

Primary research participants include demand-side respondents such as laboratory managers, procurement managers, research supervisors, as well as key opinion leaders in addition to supply-side respondents such as equipment manufacturers, custom solution and service providers who provide valuable insights on trends, research application of products and technologies, purchasing patterns, services offered and associated pricing.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-6733

The study objectives are Genetic Leukemia Detection Testing Market Report:

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-6733

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Genetic Leukemia Detection Testing market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

See original here:
Genetic Leukemia Detection Testing Market Evenly Poised To Reach A Market Value Of US$ By 2018 2028 - 3rd Watch News

Read More...

How to Become a Geneticist | EnvironmentalScience.org

Saturday, July 11th, 2020

Genetics is a field of biology that studies genes, heredity, and genetic variation. Genetic variation includes how genes become mutated or are involved in disease and aging. Environmental genetics examines how environmental factors interact with genes to cause disease, or enhance the adaptation of a species to its environment.

A geneticist is a science who studies genes, including how they are inherited, mutated, activated, or inactivated. They often study the role that genes play in disease and health. Environmental geneticists specialize in studying the interactions between genes and environmental factors that lead to adverse health effects, disease, and aging.

Geneticists study the inheritance of traits. They may focus on these events at the molecular, organism, or population level. Some treat people with genetic disorders. Many environmental geneticists try to understand how environmental factors or exposures interact with genes to cause disease.

Environmental genetics often deals with epigenetics - the process by which parts of the genome can be "turned on" or "turned off" by external environmental factors. While many traits are set in stone by genes, others are more flexible and may or may not end up being expressed. For example, if you're predisposed to a certain condition or trait due to your genetic makeup, you may or may not develop it on your own. However, being exposed to certain environmental factors such as diet and stress may cause that part of your genome to activate and be expressed. For example, genetics may make some people more susceptible to adverse health effects related to environmental factors like air pollution. Many environmental geneticists study how these interactions work.

Others study ecological genetics to expand our understanding of the role genetics plays in species' adaptations to changing environments. Ecological geneticists use population genetics for the conservation, management, and genetic improvement of species. For example, they calculate the reproduction and survival rates of a species or community. They use their knowledge of genetics to identify at-risk species and increase their genetic diversity. Some research how to genetically engineer plants that can adapt to climate change.

Regardless of specialty, most geneticists perform many of the same tasks. For example, they plan or conduct genetic research on gene expression and other topics. They keep laboratory notebooks that record their research methodology, procedures, and results. They review and interpret lab results using mathematical and statistical methods. Geneticists must keep up with scientific literature to learn about new methods, tools, and results in the field, and use that information to inform their own research. They often write grants or attend fundraising events to fund their research projects. They share their research results by writing academic journal articles and presenting at professional conferences.

Most geneticists find employment as research staff at university laboratories, government agencies, and hospitals. These jobs are available nationwide. Employment in the private sector is fairly rare.

Geneticists work a standard 40-hour week, usually in research laboratories and offices.

Geneticists earned an average annual salary of $72,720 in 2013. The full salary range is $34,590 - $124,760 annually, depending partly on location and type of employment. However, the National Human Genome Research Institute reports the median income for environmental geneticists specifically as $58,660 annually.

Table data taken from BLS (http://www.bls.gov/oes/current/oes191029.htm)

Senior geneticists often have broader responsibilities that include management of a lab or healthcare team. Such responsibilities often include:

The government predicts that job demand for geneticists as a whole will see little or no change (-2% to 2%), and that competition for basic research positions will be strong. Growth will likely be driven in part by advances in big data and hyper-computing that allow for analysis of large genetic and ecological datasets. Increased interest in the environment and an expanded focus on the medical aspects of genetics will also open up opportunities for environmental geneticists.

Students interested in environmental genetics should pursue a major in genetics, biology, environmental science, or related disciplines. Courses in biology, population biology, ecology, chemistry, math, statistics, and computer science are all very important to a career in environmental genetics.

While a bachelor's degree can be sufficient for entry-level jobs, advancement and long-term research prospects will require advanced study and continued professional development. Independent research positions and faculty positions in academia generally require doctoral degrees.

Read the rest here:
How to Become a Geneticist | EnvironmentalScience.org

Read More...

Repairing Mutations: A new gene-editing technique holds immense promise in treatment of genetic diseases – The Financial Express

Saturday, July 11th, 2020

A new development in gene-editing has sparked hope for the treatment of genetic diseases that even the revolutionary CRISPR Cas9 system couldnt help cure. Nature reports that a research team led by Joseph Mougous at the University of Washington, in 2018, discovered an enzymeDddAproduced by the bacterium Burkholderia cenocepacia that has a rather remarkable effect; when it comes across the pyrimidine cytosine (C), it changes it into the pyrimidine uracil (U). Given U is not commonly found in DNA, and behaves like the pyrimidine thymine (T), in DNA replication, it gets copied as T, which means the original C is converted into a T. While CRISPR Cas9 also relies on base editing, it relies on an RNA strand to guide the Cas9 enzyme to the region of the DNA that the researchers wish to editthis is fine for editing genes in the nucleus, but the mitochondria is a different deal.

However, Mougouss team found that DddA acts on double-stranded DNA without need Cas9 to break the DNA. David Liu, of Broad Institute of MIT and Harvard, and Mougous, worked on splitting DddA to control its base-changing effect for super-precision, instead of indiscriminate C to T conversion.

Though it is still a long way from clinical use, as the researchers who developed it have cautioned, the technique holds immense potential for research and even treatment of mitochondrial-DNA mutations that manifest as maternally-inherited conditions. Though the mitochondrial genome is considerably smaller than the nuclear genome, mutations in this have grave pathological consequences on the nervous system and muscles, including cardiac muscles. While the technique needs much more refinement, it is undoubtedly a breakthrough that can change the future for those suffering from several cardiomyopathies and encephalopathies.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know markets Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Read the original:
Repairing Mutations: A new gene-editing technique holds immense promise in treatment of genetic diseases - The Financial Express

Read More...

There is a strong genetic component to asthma, but it’s not the only risk factor – Insider – INSIDER

Friday, July 10th, 2020

Asthma is a chronic condition that causes your airways to become inflamed leading them to swell and narrow. This makes it harder for you to breathe and can cause dangerous asthma attacks.

Asthma is often linked to other health conditions like hay fever and environmental factors including air pollution. However, research also shows that carrying certain genes can put you at greater risk of developing asthma.

Here's what you need to know about what causes asthma and how it can be passed down through families.

Scientists have identified more than one hundred specific genes that may play a role in whether or not a person develops asthma. In fact, a person with at least one biological parent with asthma is 3 to 6 times more likely to develop the condition than someone whose parents don't have asthma.

However, even if you are born with asthma-related genes, you may not develop asthma unless those genes are "turned on," likely by something in your environment. "Multiple genes may be involved and they could be triggered by a number of factors, such as viral infections," says Stanley Szefler, MD, the Director of the Pediatric Asthma Research Program at Children's Hospital Colorado.

This means that if you have asthma-related genes and suffer a bad respiratory infection as a child, this could kickstart a lifelong asthma condition. However, experts say that more research is needed to fully understand how these genes interact with the environment to cause asthma in the first place.

Doctors have identified several different types of asthma including adult-onset asthma, allergic asthma, and exercise-induced asthma. Scientists have not linked any specific genes to a particular type of asthma, Szefler says. However, there is evidence that every type of asthma has a genetic component.

In a study, published in 2008 in Twin Research and Human Genetics, researchers compared the incidence of asthma in twins to determine how strongly genes affect the likelihood of developing asthma, compared with environmental factors. The results showed that genetics plays a very large role the genes account for about 70% of your risk of developing asthma.

It's important to remember that even though genes are an important risk factor for asthma:

About half of all asthma sufferers start having symptoms as children age 5 and younger. But for people who develop asthma later in life, genes are less likely to play a role. This may be because some older people develop asthma due to lifestyle choices like smoking.

In addition to genetics, asthma may be caused by:

In many cases, experts don't know why some people develop asthma while others don't. However, there are risk factors that can increase your risk. These include:

There is no way to prevent asthma, even if you start treatment early on after your symptoms develop, says Szefler. Researchers are starting to look at whether using biologic medications containing live bacteria could work to prevent asthma, Szelfer says, "but the results are several years off."

However, even if you can't prevent asthma, there are steps you can take to prevent asthma attacks:

Asthma is an ongoing condition and you should "maintain good medical follow-up to keep the disease under control," Szefler says. You will need to make an individual treatment plan with your doctor, designed to target your symptoms and help avoid your asthma triggers.

Continued here:
There is a strong genetic component to asthma, but it's not the only risk factor - Insider - INSIDER

Read More...

Think You Have Sensitive Skin? Theres One Way To Know For Sure – Well+Good

Friday, July 10th, 2020

According to science, its generally considered A-okay to blame your parents (aka your gene pool) for acne or rosacea. Now, a major study has found that sensitive skin, in general, could be passed down from generation to generation. To which we say: Thanks a lot, mom and dad!

In June, beauty corporation Procter & Gamble joined forces with 23andMe, the genetic testing service, looked at the sensitive skin condition in 23,426 participants of European ancestry whose genomes are in the 23andMe database. The research, which was published in Cosmetics, found strong associations between certain points in genomes and sensitive skin conditionsmaking this the first official connection that sensitive skin might be something thats passed down, rather than environmentally conditioned.

Sensitive skin has been a huge topic in beauty for a quite some time. Studies estimate that about 70 percent of women believe that their skin is sensitive. According to Google Search data, searches for sensitive skin have steadily risen since 2004, and are currently at an all-time high. Knowing that the sensitive skin condition stems from genetics means its now possible to avoid these triggers by building a lifestyle and skin-care regimen around them before the word go.

Currently, many people have to play a game of Clue every time their complexion experiences an inflammatory flare-up that could result in rosacea, eczema, or psoriasis. Flare-ups could be caused by sensitivities to skin-care ingredients, drinking alcohol or eating spicy foods, the temperature outdoors, or even the water used to wash products off (if it has too much mineral build-up in it).

Knowing this means we can treat patients from an earlier age based on what their family history is, says Shirley Chi, MD, a board-certified dermatologist in Los Angeles. I do that a lot in my practice, where I see a parent that has a certain skin condition like eczema, psoriasis, or severe, scarring acne, and their child starts with a few symptoms. So we start treating it early and end up getting a better handle on it than if we would let it get full-blown.

Typically, dermatologists recommend that sensitive skin types stick with a simple beauty regimen. Those with sensitive skin really have to try to limit the amount of products and chemicals that theyre exposing to their faces, says Dr. Chi. Its best to steer clear of botanical ingredients, since they can be irritating for many sensitive skin types, and Dr. Chi suggests using products with a limited number of ingredients on the label. Sensitive skin types do very well with mineral sunscreen. And products that contain silicone are good because theyre like a barrier, which protects your skin from being penetrated by chemicals.

Having a leg-up on knowing about your skin is a huge stepping stone in terms of treatment, which should be music to the ears of about 70 percent of women.

Read more from the original source:
Think You Have Sensitive Skin? Theres One Way To Know For Sure - Well+Good

Read More...

Science Round-Up: Genetic technology to be used to detect coronavirus – The Copenhagen Post – Danish news in english

Friday, July 10th, 2020

A Danish biotech sturtup will use genetic technology to diagnose COVID-19 and future pandemics in a more efficient way.

The biotech startup company Accelerbiotics, which originates from DTU Biosustain, aims to develop two technological platforms that can perform electrophoresis needed to test the disease.

Electrophoresis is a laboratory technique used to separate DNA, RNA, or protein molecules based on their size and electrical charge.

Faster and cheaper diagnosingToday, electrophoresis is mostly done manually, which makes the testing process time-consuming.

The new technology will allow purifying biomolecules such as DNA, RNA and proteins faster, cheaper and more sustainably as the electrodes will be recycled.

The platforms will be able to handle over a thousand samples at a time and read the result immediately afterwards.

HPV-related head and neck cancer cases increaseAccording to Rigshospitalet, HPV-related head and neck cancer cases have notably increased in the past 18 years in Eastern Denmark. The fact that the disease is sparked by HPV and not by smoking is also supported by the significantly increased number of non-smokers who get this form of cancer. Another striking detail is that patients tend to be younger than they used to be.

Students 3D-print fishStudents from the EU-led research project Training4CRM and DTU have created a 3D-printing technique that allows producing fish-like products based on proteins from mushrooms and peas. The project Legendary Vish is expected to be marketed to sushi restaurants by 2022.

The joy of eating chips does not depend on saltAccording to research conducted by the University of Southern Denmark, chips taste just as good when they contain 30 percent less salt. The researchers have tested 200 young people and have been surprised by the result, which suggests that the pleasure of eating chips is not dependent on salt content. As 9 out of 10 Danes eat too much salt, the finding is relevant as this ingredient can be significantly reduced without affecting the overall taste.

View post:
Science Round-Up: Genetic technology to be used to detect coronavirus - The Copenhagen Post - Danish news in english

Read More...

Genetic testing and hitching a ride with the British; In The News for July 10 – Kamloops This Week

Friday, July 10th, 2020

In The News is a roundup of stories from The Canadian Press designed to kickstart your day. Here is what's on the radar of our editors for the morning of July 10 ...

What we are watching in Canada ...

OTTAWA The Supreme Court of Canada is slated to rule this morning on the constitutionality of a federal law that forbids companies from making people undergo genetic testing before buying insurance or other services.

The Genetic Non-Discrimination Act also outlaws the practice of requiring the disclosure of existing genetic test results as a condition for obtaining such services or entering into a contract.

The act is intended to ensure Canadians can take genetic tests to help identify health risks without fear they will be penalized when seeking life or health insurance.

The law, passed three years ago, is the result of a private member's bill that was introduced in the Senate and garnered strong support from MPs despite opposition from then-justice minister Jody Wilson-Raybould.

The Quebec government referred the new law to the provincial Court of Appeal, which ruled in 2018 that it strayed beyond the federal government's jurisdiction over criminal law.

The Canadian Coalition for Genetic Fairness then challenged the ruling in the Supreme Court of Canada, which heard the appeal last October.

---

Also this ...

OTTAWA Canadian troops are being forced to hitch a ride with the British military to get to and from Latvia due to a shortage of working planes.

A CC-150 Polaris was to carry about 120 Canadian soldiers to Latvia on Wednesday and fly back with a similar number of returning troops.

Yet the Defence Department says those plans changed after a problem was found with the plane's landing gear, which is when the military asked the British for help.

The Air Force has three Polaris capable of ferrying personnel to different parts of the world but the Defence Department says the other two were unavailable.

One is currently ferrying troops to and from the Middle East while the third which normally serves as the prime minister's plane is out of commission until at least January after a hangar accident last October.

Defence Department spokeswoman Jessica Lamirande says the British plane took off with the 120 departing troops on Thursday and will return with a similar number of soldiers in the coming days.

---

What we are watching in the U.S. ...

International students worried about a new immigration policy that could potentially cost them their visas say they feel stuck between being unnecessarily exposed during the coronavirus pandemic and being able to finish their studies in the United States.

The students from countries such as India, China and Brazil say they are scrambling to devise plans after federal immigration authorities notified colleges this week that international students must leave the U.S. or transfer to another college if their schools operate entirely online this fall.

Some say they are considering the possibility of returning home or moving to Canada.

---

What we are watching elsewhere in the world ...

SEOUL The sudden death of the Seoul mayor is triggering an outpouring of public sympathy but also questions about his behaviour.

Park Won-sun was found dead in the South Korean capital, hours after his daughter reported him missing.

Media reports say one of his secretaries lodged a complaint with police over his alleged sexual harassment.

Many mourn Park's death, while others worry sympathy for him could lead to a criticism of the woman who filed the complaint.

Despite gradually improvements in women's rights in recent years, South Korea remains a male-centred society.

---

Today in 1912...

Montreal's George Hodgson won Canada's first Olympic swimming gold medal. He set a world record of 22 minutes flat in the 1,500-metre freestyle at the Games in Stockholm. That record lasted 11 years. Four days later, Hodgson won the 400-metre freestyle. Canada did not capture another Olympic swimming title until 1984.

---

The Canadian economy ...

Statistics Canada is set this morning to give a snapshot of the job market as it was last month as pandemic-related restrictions eased and reopenings widened.

Economists expect the report will show a bump in employment as a result, further recouping some of the approximately three million jobs lost over March and April.

Financial data firm Refinitiv says the average economist estimate for June is for employment to increase by 700,000 jobs and the unemployment rate to fall to 12.0 per cent.

The unemployment rate in May was a record-high 13.7 per cent, a far turn from the record low of 5.5 per cent recorded in January.

The Bank of Canada and federal government say the worst of the economic pain from the pandemic is behind the country, but Canada will face high unemployment and low growth until 2021.

The economic outlook released by the Liberal government Wednesday forecasted the unemployment rate to be 9.8 per cent for the calendar year, dropping to 7.8 per cent next year based on forecasts by 13 private sector economists.

---

This report by The Canadian Press was first published July 10, 2020.

See the article here:
Genetic testing and hitching a ride with the British; In The News for July 10 - Kamloops This Week

Read More...

For The First Time, Scientists Find a Way to Make Targeted Edits to Mitochondrial DNA – ScienceAlert

Friday, July 10th, 2020

Most cells in your body come with two genetic libraries; one in the nucleus, and the other inside structures called mitochondria - also known as the 'powerhouses of the cell'.

Until now, we've only had a way to make changes to one.

A combined effort by several research teams in the US has led to a process that could one day allow us to modify the instructions making up the cell's 'other' genome, and potentially treat a range of conditions that affect how we power our bodies.

The molecular foundation of this revolutionary gene editing tool is a toxin called DddA, secreted by the bacterium Burkholderia cenocepacia to sabotage other microbes when competition over resources turns serious.

Researchers from the University of Washington have had an interest in the toxin's talents for a while, finding it converts a nucleic acid base called cytosine into a different one commonly found in RNA, called uracil.

It's far from the first time researchers have looked to bacterial weapons for clues on how to tweak DNA in this way. In fact, a whole family of so-called deaminase enzymes had already been put to use in genetic engineering.

Unfortunately deaminase enzymes tend to only perform their code-swapping trick on single strands of DNA.

To get around this, another research team from the Broad Institute of MIT and Harvard combined their code-swapping deaminase with CRISPR technology, which entails using an RNA template to identify the sequence and then using enzymes to unzip the strands and make changes.

That isn't too much of a problem when you want to make edits to double strands of DNA inside something as welcoming as a cell's nucleus. But smuggling the RNA templates through the more selective membrane of a mitochondrion isn't quite so simple.

That's becausemore than a billion years ago, mitochondria were organisms in their own right, and over time they evolved to share responsibilities with the cells they now occupy, being delegated the business of breaking down glucose for power.

While many mitochondrial genes have long since been filed away in the host's nucleus, these tiny power units have held onto a few important sequences, which are tightly locked away behind a veil of membranes that don't take kindly to stray bits of RNA wafting through.

Fortunately, DddA had a unique talent for making changes to both DNA strands, opening the way to ditching CRISPR and its bulky RNA template in favour of alternative methods for targeting the sequence you want to change.

That third piece of the puzzle came in the form of an old school genetic engineering tool called a transcription activator-like effector, or TALE.

This class of enzyme can be tailored to find specific nucleic acid codes and break them apart. Just the thing for guiding a cytosine-swapping toxin into place.

Teamed up with DddA, a specially crafted TALE enzyme can find a target sequence inside mitochondria and turn any cytosine it finds into a uracil, which will later transform into a similar DNA-specific base called thymine.

In testing, this change occurred roughly half of the time.

A fifty-fifty change might not seem like a big win, but given there were no signs of potentially disastrous changes outside of target sequences, it makes for a promising precision engineering tool.

What's more, given there's no other contenders for editing mitochondrial genes, it's a landmark achievement with even this success rate.

Just as mutations in nuclear DNA can give rise to a wide variety of health conditions, mutations in the mitochondria's genes can also be problematic, affecting anything from brain development to muscle growth, energy levels, metabolism, and immunity.

Usually (though not always) passed through the eggs down from mothers, mitochondria and any damaging mutations can be inherited through the generations. Right now the best we might be able to do is combine cells from two different mothers to remove affected mitochondria.

But with this new DddA technology, we might finally be able to create animal models that mimic a range of debilitating mitochondrial conditions in humans. And, maybe one day, even fix them inside our own bodies.

This research was published in Nature.

Read the rest here:
For The First Time, Scientists Find a Way to Make Targeted Edits to Mitochondrial DNA - ScienceAlert

Read More...

Generational Equity Advises New Generation Genetics in its Sale to Swissgenetics International – Business Wire

Thursday, July 9th, 2020

DALLAS--(BUSINESS WIRE)--Generational Equity, a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client, New Generation Genetics to Swissgenetics International. The acquisition closed July 1, 2020 and details were not disclosed.

New Generation Genetics (NGG), located in Fort Atkinson, Wisconsin, has a primary goal of providing its customers with the best Brown Swiss genetics in the industry. NGG focuses solely on Brown Swiss, giving them the advantage over their competitors. The Company has over 50 years of Brown Swiss A.I. experience combined. They currently offer top bulls for Milk, Type, Net Merit, Sire Conception Rate (SCR), Fat, Protein, and PPR Index. They currently sample only the top genomic bulls and continue to lead the breed by sampling 12 young bulls per year.

Swissgenetics International is located in Zollikofen, Switzerland. Successful milk and beef producers rely on sustainable breeding strategies and professional production methods. To achieve this, high-performance and healthy animals are needed. The genetics programs from Swissgenetics are aligned consistently to meet and exceed these requirements. Through the testing programs operated in partnership with breeders and breeding organizations, marketable and future-oriented genetics are developed at an international level. Beneficial breeding cooperation assumes mutual trust between genetics providers and breeders. This requires high levels of competence and transparency on both sides. Swissgenetics is a leader in this field.

Generational Equity Executive Managing Director of M&A Central Region, Michael Goss, and his team lead by Managing Director Mergers & Acquisitions, Stephen Dinehart, with support from Managing Director Mergers & Acquisition, Ryan Johnson, successfully closed the deal. Senior Managing Director Joe Van Voorhis established the initial relationship with NGG.

This is a great acquisition for the Brown Swiss producer family combining two of the major players in Brown Swiss Genetics, said Dinehart. It is a win for both the customers and employees of Swissgenetics and NGG.

About Generational Equity

Generational Equity, Generational Capital Markets (member FINRA/SIPC), Generational Wealth Advisors, Generational Consulting Group, and DealForce are part of the Generational Group, which is headquartered in Dallas and is one of the leading M&A advisory firms in North America.

With over 250 professionals located throughout North America, the companies help business owners release the wealth of their business by providing growth consulting, merger, acquisition, and wealth management services. Their six-step approach features strategic and tactical growth consulting, exit planning education, business valuation, value enhancement strategies, M&A transactional services, and wealth management.

The M&A Advisor named the company the 2016, 2017, and 2018 Investment Banking Firm of the Year. For more information, visit https://www.genequityco.com/ or the Generational Equity press room.

Read more from the original source:
Generational Equity Advises New Generation Genetics in its Sale to Swissgenetics International - Business Wire

Read More...

Could induced pluripotent stem cells be the breakthrough genetics has been waiting for? – The New Economy

Thursday, July 9th, 2020

Embryonic stem cells. The ethical issues associated with stem cell research could be resolved through the use of induced pluripotent stem cells, which are derived from fully committed and differentiated cells of the adult body

The almost miraculous benefits that stem cells may one day deliver have long been speculated on. Capable of becoming different types of cells, they offer huge promise in terms of transplant and regenerative medicine. It is, however, also a medical field that urges caution one that must constantly battle exaggeration. If stem cells do in fact hold the potential to reverse the ageing process, for example, then such breakthroughs remain many years away.

Recently, though, the field has had cause for excitement. In 2006, Japanese researcher Shinya Yamanaka discovered that mature cells could be reprogrammed to become pluripotent, meaning they can give rise to any cell type of the body. In 2012, the discovery of these induced pluripotent stem cells (iPSCs) saw Yamanaka and British biologist John Gurdon awarded the Nobel Prize in Physiology or Medicine. Since then, there has been much talk regarding the potential iPSCs possess, not only for the world of medicine, but for society more generally, too.

A big stepHistorically, one of the major hurdles preventing further research into stem cells has been an ethical one. Until the discovery of iPSCs, embryonic stem cells (ESCs) represented the predominant area of research, with cells being taken from preimplantation human embryos. This process, however, involves the destruction of the embryo and, therefore, prevents the development of human life. Due to differences in opinion over when life is said to begin during embryonic development, stem cell researchers face an ethical quandary.

The promise of significant health benefits and new revenue streams has led some clinics to offer unproven stem cell treatments to individuals

With iPSCs, though, no such dilemmas exist. IPSCs are almost identical to ESCs but are derived from fully committed and differentiated cells of the adult body, such as a skin cell. Like ESCs, iPSCs are pluripotent and, as they are stem cells, can self-renew and differentiate, remaining indefinitely propagated and retaining the ability to give rise to any human cell type over time.

One important distinction to make is that both ESCs and iPSCs do not exist in nature, Vittorio Sebastiano, Assistant Professor (Research) of Obstetrics and Gynaecology (Reproductive and Stem Cell Biology) at Stanford Universitys Institute for Stem Cell Biology and Regenerative Medicine, told The New Economy. They are both beautiful laboratory artefacts. This means that at any stage of development, you cannot find ESCs or iPSCs in the developing embryo, foetus or even in the postnatal or adult body. Both ESCs and iPSCs can only be established and propagated in the test tube.

The reason neither ESCs nor iPSCs can be found in the body is that they harbour the potential to be very dangerous. As Sebastiano explained, these cells could spontaneously differentiate into tumorigenic masses because of their intrinsic ability to give rise to any cell type of the body. Over many years of research, scientists have learned how to isolate parts of the embryo (in the case of ESCs) and apply certain culture conditions that can lock cells in their proliferative and stem conditions. The same is true for iPSCs.

To create iPSCs, scientists take adult cells and exogenously provide a cocktail of embryonic factors, known as Yamanaka factors, for a period of two to three weeks. If the expression of such factors is sustained for long enough, they can reset the programme of the adult cells and establish an embryonic-like programme.

Turning back the clockThere is already a significant body of research dedicated to how stem cells can be used to treat disease. For example, mesenchymal stem cells (usually taken from adult bone marrow) have been deployed to treat bone fractures or as treatments for autoimmune diseases. It is hoped that iPSCs could hold the key for many more treatments.

Global stem cell market:25.5%Expected compound annual growth rate (2018-24)$467bnExpected market value (2024)

IPSCs are currently utilised to model diseases in vitro for drug screening and to develop therapies that one day will be implemented in people, Sebastiano explained. Given their ability to differentiate into any cell type, iPSCs can be used to differentiate into, for example, neurons or cardiac cells, and study specific diseases. In addition, once differentiated they can be used to test drugs on the relevant cell type. Some groups and companies are developing platforms for cell therapy, and I am personally involved in two projects that will soon reach the clinical stage.

Perhaps the most exciting prospects draw on iPSCs regenerative properties. Over time, cells age for a variety of reasons namely, increased oxidative stress, inflammation and exposure to pollutants or sunlight, among others. All these inputs lead to an accumulation of epigenetic mistakes those that relate to gene expression rather than an alteration of the genetic code itself in the cells, which, over time, results in the aberrant expression of genes, dysfunctionality at different levels, reduced mitochondrial activity, senescence and more besides. Although the epigenetic changes that occur with time may not be the primary cause of ageing, the epigenetic landscape ultimately affects and controls cell functionality.

What we have shown is that, if instead of being expressed for two weeks we express the reprogramming factors for a very short time, then we see that the cells rejuvenate without changing their identity, Sebastiano said. In other words, if you take a skin cell and express the reprogramming genes for two to four days, what you get is a younger skin cell.

By reprogramming a cell into an iPSC, you end up with an embryonic-like cell the reprogramming erases any epigenetic errors. If expressed long enough, it erases the epigenetic information of cell identity, leaving embryonic-like cells that are also young.

Slow and steadyAs with any scientific advancement, financial matters are key. According to Market Research Engine, the global stem cell market is expected to grow at a compound annual growth rate of 25.5 percent between 2018 and 2024, eventually reaching a market value of $467bn. The emergence of iPSCs has played a significant role in shaping these predictions, with major bioscience players, such as Australias Mesoblast and the US Celgene, working on treatments involving this particular type of stem cell.

The business potential around stem cell research is huge, Sebastiano told The New Economy. [Particularly] when it comes to developing cell banks for which we have detailed genetic information and, for example, studying how different drugs are toxic or not on certain genetic backgrounds, or when specific susceptibility mutations are present.

Unfortunately, even as the business cases for iPSC treatments increase, a certain degree of caution must be maintained. The promise of significant health benefits and new revenue streams has led some clinics to offer unproven stem cell treatments to individuals. There have been numerous reports of complications emerging, including the formation of a tumour following experimental stem cell treatment in one particular patient, as recorded in the Canadian Medical Association Journal last year. Such failures risk setting the field back years.

The challenge for researchers now will be one of balance. The potential of iPSCs is huge both in terms of medical progress and business development but can easily be undermined by misuse. Medical advancements, particularly ones as profound as those associated with iPSCs, simply cannot be rushed.

Read this article:
Could induced pluripotent stem cells be the breakthrough genetics has been waiting for? - The New Economy

Read More...

New study finds love of affection heavily attributed to genetics in women – Arizona Daily Wildcat

Thursday, July 9th, 2020

Nature versus nurture: A debate that may only be applicable to women when it comes to a love of affection. A new study found a "latent genetic factor" accounting for up to 48% variance in affection for women with null effects in men.

Genes play a really important role in how affectionate women become as adults, said Kory Floyd, a professor of communication at the University of Arizona, specializing in the study of affection. It appears to play virtually no role in how affectionate men become we still are trying to figure out why.

According to Floyd, the original goal of the study was to answer the broad question of why many people are more affectionate than others. He described that throughout life, it is easy to observe levels of affection among people; some are very affectionate, some are somewhere between and some are just not comfortable with a lot of affection.

Even though the team assumed that environmental factors such as affectionate or non-affectionate households would play a big role, they also wanted to see how much of this trait is genetic.

The question wasnt which one is it is it nature or is it nurture we assumed that it would be a combination of both of those things, Floyd said.

To gather this information, Floyd worked with two other professors to find answers to their questions. The first professor Colter Ray was a former Ph.D. student of his who is now an interpersonal communication professor at San Diego State University. The second Chance York was an interpersonal professor at Kent State University specializing in behavioral genetics.

The three set off to find answers to their questions on the genetics of affection through surveying 464 pairs of twins, all ages 19 to 84, according to UANews.

Some of the pairs were identical twins, meaning that they inherited 100% of the same genes and some were fraternal twins, meaning that they inherited about 50% of the same genes.

The team assumed that if affection has a strong genetic component to it, then identical twins would likely show more similar levels of affection than fraternal twins.

What we expect to find is that the scores of twins who are identical are more similar to each other than the scores of twins who are fraternal because they are more closely related genetically, Floyd said.

In the survey sent out, every participant was able to report on their levels of affection using a measurement system that would assess it. Essentially, Floyd and the team wanted to find how similar scores would be within pairs.

Through the survey, it was found that for the female participants alone, around 48% of affection levels could be attributed to genetics and 52% could be attributed to environmental factors. In the males, genetic components played absolutely no role.

Floyd explained that this study brings the discipline of communication into a new realm.

In my field, we have a very strong assumption that differences between people in terms of their social behavior are almost entirely environmental, Floyd said. Unlike fields like psychology, for example, we dont have a history of looking at biology or genetics or heritability as explanations for social behavior.

He believes that this study could lead people to question the assumption in the communication discipline that most social behaviors are purely products of an environment.

Recently, Floyd has also participated in research on the concept of skin hunger. According to Psychology Today, skin hunger is a deep longing and aching desire for physical contact with another person.

During the times of COVID-19, the concept of skin hunger could not be more relevant.

I think a lot of people right now are really feeling like, I miss getting hugs, I miss holding hands or kissing or putting my arm around somebody, Floyd described. Its really the one thing that social media and Skype and Zoom dont allow us to do.

In research on deprivation of touch in the past, Floyd has found that it can definitely increase negative feelings like loneliness, anxiety, sleep issues and even a depressed immune system.

Though Floyd has not found any solutions to this issue, he believes that there are many ways to cope with the deprivation of physical attention. A major coping mechanism that Floyd suggests for those struggling with such a type of deprivation is to be around animals.

Petting a dog, petting a cat, petting a horse can have some of the same benefits in terms of calming us, in terms of anxiety reduction, in terms of stress reduction, Floyd said.

So, regardless of sex and your level of genetic cravings for affection, a reliable coping mechanism for the skin hunger you may be facing during these times could be to invest in a dog or cat.

Follow Quinn McVeigh on Twitter

Originally posted here:
New study finds love of affection heavily attributed to genetics in women - Arizona Daily Wildcat

Read More...

Sixth Circuit: A Genetic Mutation That Interferes With Normal Cell Growth May Qualify as a Disability Under the ADA – JD Supra

Thursday, July 9th, 2020

In a case of first impression at the circuit level, the Sixth Circuit Court of Appeals reversed dismissal of a disability discrimination complaint because the plaintiff had plausibly alleged a condition covered by the Americans with Disabilities Act (ADA) based on a genetic mutation causing abnormal cell development.

Disability for purposes of the ADA is broadly defined as a physical or mental impairment that substantially limits a major life activity. The ADA instructs that the definition of disability shall be construed in favor of broad coverage of individuals to the maximum extent permitted by the terms of the ADA.

In Darby v. Childvine, Inc., et al., No. 1:18-cv-0669, Plaintiff Sherryl Darby alleged that she underwent a double-mastectomy after genetic testing resulted in a positive match for the BRCA1 gene. Although her employer, Childvine Inc., approved her request to use vacation and sick time to cover her absence for surgery, when Darby returned to work, her supervisor told her she had been terminated. Darby alleged that the stated reasons for her termination an unpleasant attitude, dress code violations and by being unable to work were pretexual. Childvine moved to dismiss the complaint. While the motion was pending, discovery revealed that Darby was never diagnosed with cancer, but had a family history of cancer and the genetic mutation BRCA1. The parties stipulated to certain admissions, including that [t]he BRCA1 gene is an impairment that substantially limits normal cell growth. And that, because of her genetic match, Darbys doctors urged her to have a double mastectomy. In dismissing Darbys complaint, the district court concluded that Darby had offered no statutory, regulatory, or caselaw support for her [argument] that the BRCA1 gene, like cancer itself, is a physical impairment that substantially limits normal cell growth.

The Sixth Circuit reversed and remanded. After reviewing the definition of disability in the ADA and the federal regulations, the court posed the following question: Has Darby plausibly alleged that her impairment substantially limits her normal cell growth as compared to the general population due to both a genetic mutation (BRCA1) that limits her normal cell growth and a medical diagnosis of abnormal epithelial cell growth serious enough to warrant a double mastectomy? The answer is yes.

In reaching this conclusion, the court specifically noted that the 2008 amendments to the ADA included normal cell growth in the definition of a major life activity. The court also pointed out that the ADAs implementing regulations cite cancer as a condition that at a minimum will qualify as an impairment that substantially limits a major life activity. Because this language suggests a floor rather than a ceiling, Darbys gene mutation and abnormal cell growth qualify as a disability under the ADA despite not being cancerous. However, the court did not go so far as to say that a genetic mutation that merely predisposes an individual to other conditions, such as cancer, is itself a disability under the ADA. The terms of the Act do not reach that far.

The court emphasized the narrowness of both the issue before the court and its holding. Specifically, the court did not decide whether Darbys condition in fact falls under the ADAs definition of a disability.

Alternatively, the court essentially found that the Darbys condition could be considered a disability under the ADA if certain conditions were met, such as: that her pre-cancerous cells constitute a substantial limitation on her normal cell growth and that her genetic mutation caused those pre-cancerous cells. Those issues require consideration beyond the four corners of Darbys complaint, and may require an expert to prove. Thus, although Darbys factual allegations were sufficient to survive a motion to dismiss, more would be required to survive summary judgment. The court reversed and remanded with instructions for the lower court to consider the claim under Ohio law as well as the ADA.

Despite the narrowness of the Sixth Circuits holding, it provides important direction as to what may constitute a disability under the ADA in cases of genetic mutation and the attendant medical conditions. And, though the court did not resolve whether Darby had adequately pleaded her failure to accommodate claim in this case, generally employers should engage in an interactive process with employees when presented with a medically-documented request for accommodation and provide a reasonable accommodation when possible.

Link:
Sixth Circuit: A Genetic Mutation That Interferes With Normal Cell Growth May Qualify as a Disability Under the ADA - JD Supra

Read More...

First Extensive Validation Study of Saphyr for Constitutional Genetic Disorders by European Consortium Shows 100% Concordance to Standard Cytogenetics…

Thursday, July 9th, 2020

SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that two top cytogeneticists from leading institutions in The Netherlands and France presented their research data as part of a multicentric, international effort to compare data generated with Bionanos Saphyr system against gold standard cytogenetic methods consisting of karyotyping, FISH, and/or chromosomal microarray in patients with a variety of constitutional or inherited genetic disorders and in patients with leukemias. In back-to-back online presentations, each showed 100% concordance between Saphyr and standard cytogenetics along with other discoveries that extend the capabilities of the current standard of care.

Summary of data presentations:

In a webinar originally hosted by LabRoots on Friday, June 22, Dr. Laila El Khattabi from the Cochin Hospital in Paris, France discussed how Saphyr improved structural variant detection for constitutional chromosomal aberrations in her research. The data originate from an international multi-center effort between the hospitals of Paris-Cochin, Lyon and Clermont-Ferrand and the Radboud University Medical Center in the Netherlands, as part of the first international consortium to validate Saphyr for constitutional cytogenetic analysis. The consortium compared the performance of Saphyr against the combination of karyotyping, FISH and array-based methods in 85 samples with a variety of constitutional aberrations including deletions, duplications, balanced and unbalanced translocations, inversions, ring chromosomes and aneuploidies in patients with intellectual disabilities and recurrent miscarriages. Saphyr showed 100% concordance with gold standard methods in these 85 samples. Dr. El Khattabi expressed the consortiums confidence in Saphyrs potential to largely replace standard cytogenetic testing methods in the future. A manuscript describing the study results will be submitted for publication in the coming weeks.

Dr. Alexander Hoischen from Radboud University Medical Center described how Bionano genome imaging identified likely pathogenic variants in 25% of unsolved rare disease cases analyzed with Saphyr. Dr. Hoischen presented two of these research cases, which involved families with undiagnosed genetic disorders. The first case involved a rare and aggressive childhood tumor named Atypical Teratoid Rhabdoid Tumor (ATRT) in which Saphyr detected an insertion in the SMARCB1 gene in a family affected by ATRT, while MLPA and next generation sequencing were unable to identify this variant. In a family affected by intellectual disability, Saphyr identified a single de novo deletion affecting the NSF gene, undetected by chromosomal microarray, whole exome and whole genome sequencing and long read sequencing. This deletion was confirmed to be de novo in the child through PCR validation. Finally, Dr. Hoischen provided an update on his retrospective comparative study on leukemias, which he presented at ESHG 2020 and is expected to be submitted for peer-review publication in the near future. The study showed 100% concordance between Bionanos Saphyr system and standard cytogenetics in 48 leukemia patients. Additionally, Saphyr identified novel events previously undetected by traditional cytogenetic methods, many of them being rare inter-chromosomal translocations causing gene fusions never described before, opening potential new avenues of research in precision medicine and drug development. Dr. Hoischen concluded that Saphyr has value in solving unanswered rare disease cases and has the potential to replace classical cytogenetics methods.

At the ESHG 2020 conference, Dr. Uwe Heinrich, representing MVZ Martinsried, Germany presented that Bionano was able to confirm all known large rearrangements in a cohort of patients with intellectual disability, developmental disorders and chromosomal aberrations. Drs. Hoischen and Heinrich announced that their respective teams are planning to seek accreditation for the Saphyr system, to start offering Bionanos genome imaging as part of a stepwise diagnosis, and to subsequently replace chromosomal microarray with Saphyr altogether later on.

Erik Holmlin, Ph.D., CEO of Bionano Genomics commented: We previously demonstrated the notable performance of Saphyr in leukemia studies across the globe, but the international study presented by Dr. El Khattabi demonstrates that Saphyr performs equally well in genetic diseases such as intellectual disabilities and subfertility. Saphyr showed 100% concordance with traditional cytogenetic methods and made additional discoveries in both leukemia patients and in those with constitutional disorders. We believe that Saphyr is capable of replacing traditional cytogenetic methods and consolidating these outdated methods into a single digital platform that is faster, less expensive and has lower manual labor needs, while providing greater accuracy than these methods.

A recording of the presentation by Drs. El Khattabi and Hoischen can be viewed at https://bionanogenomics.com/library/webinars/

About Bionano GenomicsBionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Bionanos Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. For more information, visitwww.bionanogenomics.com.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our intentions, beliefs, projections, outlook, analyses or current expectations concerning the Saphyr System; the intended use of Saphyr by the institutions identified in this press release; expectations regarding the rate and extent of adoption of Saphyr in research and clinical settings; and the general effectiveness and utility of Saphyr, including its ability to replace traditional cytogenetic methods and enable discoveries that can contribute to treatment of disease. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated withour business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

ContactsCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com

Investor Relations Contact:Ashley R. RobinsonLifeSci Advisors, LLC+1 (617) 430-7577arr@lifesciadvisors.com

Media Contact:Kirsten ThomasThe Ruth Group+1 (508) 280-6592kthomas@theruthgroup.com

Read the original post:
First Extensive Validation Study of Saphyr for Constitutional Genetic Disorders by European Consortium Shows 100% Concordance to Standard Cytogenetics...

Read More...

Predictive Genetic Testing and Consumer/Wellness Genomics Market Analytical Overview and Size(Value and Volume) by 2025 – Cole of Duty

Thursday, July 9th, 2020

Predictive Genetic Testing and Consumer/Wellness Genomics Market: Snapshot

Genetic testing comprises examination of ones DNA. The term DNA refers to the chemical database that is responsible for conveying the instructions for functions that need to be performed by the body. Genetic testing is capable of revealing changes or mutations in the genes of living beings, which might result in any kind of disease or illness in the body.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1274

Predictive genetic testingrefers to the utilization of genetic testing methods in an asymptomatic individual to make a prediction about risk of contacting particular disease in future. These tests are regarded as representation of emerging class of medical tests, which differ in fundamental ways from the usual diagnostic tests.

The global predictive genetic testing and consumer/wellness genomics marketis likely to gather momentum owing to the benefits offered by predictive genetic testing.

The benefits of predictive genetic testing are

The global predictive genetic testing and consumer/wellness genomics marketis influenced by reducing cost of genetic sequencing and technological advancement in the field of genetics. North America is expected to emerge as a prominent region for the global predictive genetic testing and consumer/wellness genomics market in years to come due to high adoption rates of latest technologies in all fields.

Over centauries human DNA has undergone tremendous alteration due to evolutionary and lifestyle changes. They have led to both, advantages and disadvantages over the years. Some have given the mankind a deserving edge over other creatures while the others have led to disorders and diseases. Predictive genetic testing and consumer/wellness genomics market thrives on the growing demand for understanding the lineage of a certain gene pool to identify disorders that could manifest in the later or early stage of a human life. The surging demand for understanding the family history or studying the nature of certain diseases has given the global market for predictive genetic testing and consumer/wellness genomics market adequate fodder for growth in the past few years.

This new class of medical tests are aimed at reducing the risk of morbidity and mortality amongst consumers. The thorough surveillance and screening of a certain gene pool can allow an individual to avoid conditions that disrupt normal existence through preventive measures. The clinical utility of these tests remains unassessed. Therefore, increasing research and development by pharmaceutical companies to develop new drugs by understanding diseases and disorders is expected to favor market growth.

Unlike conventional diagnostic testing, predictive genetic testing identifies the risk associated with potential conditions. In certain cases it is also capable of stating when the disease may appear and the how severe will it be. Thus, this form of testing is expected to allow consumers to take up wellness measurements well in time to lead a life of normalcy, characterized by good health.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1274<ype=S

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Overview

Predictive genetic testing are used to identify gene mutations pertaining to the disorders that surface at a considerably later stage in life after birth. These tests are particularly beneficial for people from a family with a history of genetic disorder, although they themselves show no symptoms of the disorder at the time of testing. Genetic testing promises to revolutionize the healthcare sector, providing crucial diagnostic details related to diverse verticals such as heart disease, autism, and cancer. As the healthcare sector touches new peaks, the global predictive genetic testing and consumer/wellness genomics market is projected to expand at a healthy growth rate during the forecast period of 2017 to 2025.

This report on the global market for predictive genetic testing and consumer/wellness genomics analyzes all the important factors that may influence the demand in the near future and forecasts the condition of the market until 2025. It has been created using proven research methodologies such as SWOT analysis and Porters five forces. One of the key aspect of the report is the section on company profiles, wherein several leading players have been estimated for their market share and analyzed for their geographical presence, product portfolio, and recent strategic developments such as mergers, acquisitions, and collaborations.

The global predictive genetic testing and consumer/wellness genomics market, on the basis of test type, can be segmented into predictive testing, consumer genomics, and wellness genetics. The segment of predictive testing can be sub-segmented into genetic susceptibility test, predictive diagnostics, and population screening programs, whereas the segment of wellness genetics can be further divided into nutria genetics, skin and metabolism genetics, and others.

By application, the market can be segmented into breast and ovarian cancer screening, cardiovascular screening, diabetic screening and monitoring, colon cancer screening, Parkinsons or Alzheimers disease, urologic screening or prostate cancer screening, orthopedic and musculoskeletal screening, and other cancer screening. Geographically, the report studies the opportunities available in regions such as Asia Pacific, Europe, North America, and the Middle East and Africa.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Trends and Opportunities

Increasing number of novel partnership models, rapidly decreasing cost of genetic sequencing, and introduction of fragmented point-solutions across the genomics value chain as well as technological advancements in cloud computing and data integration are some of the key factors driving the market. On the other hand, the absence of well-defined regulatory framework, low adoption rate, and ethical concerns regarding the implementation, are expected to hinder the growth rate during the forecast period. Each of these factors have been analyzed in the report and their respective impacts have been anticipated.

Currently, the segment of predictive genetic cardiovascular screening accounts for the maximum demand, and increased investments in the field is expected to maintain it as most lucrative segment. On the other hand, more than 70 companies are currently engaged in nutrigenomics, which is expected to further expand the market.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Regional Outlook

Owing to robust healthcare infrastructure, prevalence of cardiovascular diseases, and high adoptability rate of new technology makes North America the most lucrative region, with most of the demand coming from the country of the U.S. and Canada. Several U.S. companies hold patents, which further extends the outreach of the market in the region of North America.

Companies mentioned in the research report

23andMe, Inc, BGI, Genesis Genetics, Illumina, Inc, Myriad Genetics, Inc, Pathway Genomics, Color Genomics Inc., and ARUP Laboratories are some of the key companies currently operating in global predictive genetic testing and consumer/wellness genomics market. Various forms of strategic partnerships with operating company and smaller vendors with novel ideas helps these leading players maintain their position in the market.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1274

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

See the original post here:
Predictive Genetic Testing and Consumer/Wellness Genomics Market Analytical Overview and Size(Value and Volume) by 2025 - Cole of Duty

Read More...

Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing…

Thursday, July 9th, 2020

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases, today announced the publication of data in the journal Nature Communications that support the companys proprietary approach to precisely upregulate protein expression using TANGO (Targeted Augmentation of Nuclear Gene Output) antisense oligonucleotides (ASOs).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005385/en/

TANGO (Targeted Augmentation of Nuclear Gene Output)

Stoke was founded on the idea that we could use unique insights in RNA biology to do something that has never been done before, said Isabel Aznarez, Ph.D., Co-Founder and Vice President, Head of Biology of Stoke Therapeutics and the corresponding author on the paper. Rather than address genetic diseases by replacing, repairing or editing faulty genes, we set out to increase or stoke protein output from healthy genes. These data show that we can increase full-length, fully functional protein expression from a variety of healthy genes, which supports our hypothesis and may lead to a new way of treating severe genetic diseases.

To evaluate the approach broadly, Stoke selected four gene targets that vary in type and abundance of non-productive splicing events, gene size and protein function: PCCA (propionic acidemia); SYNGAP1 (autosomal dominant mental retardation 5); CD274 (autoimmune diseases, including uveitis); and SCN1A (Dravet syndrome). Stoke designed TANGO ASOs to target the non-productive splicing events in these genes and their activity was evaluated. Dose-dependent reductions of non-productive mRNA were observed to lead to increases in both productive mRNA and protein levels for each of the target genes.

More than 10,000 genetic diseases are caused by mutations in a single gene, however, current therapeutic approaches address as few as 5% of these diseases. In the experiments published today, a proprietary bioinformatics analysis of RNA sequencing datasets was used to identify a variety of non-productive alternative-splicing events that lead to mRNA degradation and limit protein production. Stoke found 7,757 unique genes that contained at least one non-productive event, of which 16% (1,246) were associated with causing a specific disease.

A link to the publication, Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression, can be found here: https://www.nature.com/articles/s41467-020-17093-9

Pre-mRNA Splicing and TANGO

Human cells naturally regulate protein production to maintain health. Pre-mRNA splicing, including alternative splicing, is an important mechanism used to regulate how much protein and which protein variant is produced. During splicing, introns are removed and exons are joined together to generate the mRNA template that carries the code to synthesize proteins. More than one third of alternative splicing events in mammals do not produce functional proteins and lead to mRNA degradation through nonsense-mediated mRNA decay (NMD). TANGO ASOs act at the pre-mRNA level and prevent non-productive alternative splicing so that the body produces more protein-coding mRNA and thus more protein. This approach is particularly applicable to diseases that are caused by insufficient protein production.

About Stoke Therapeutics

Stoke Therapeutics, Inc. (Nasdaq: STOK), is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. The companys lead investigational new medicine is STK-001, a proprietary antisense oligonucleotide (ASO) that has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome, a severe and progressive genetic epilepsy. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the company on Twitter at @StokeTx.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about Companys proprietary approach to precisely upregulate protein expression using TANGO ASOs and the potential benefits thereof. These forward-looking statements may be accompanied by such words as aim, anticipate, believe, could, estimate, expect, forecast, goal, intend, may, might, plan, potential, possible, will, would, and other words and terms of similar meaning. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: risks related to the direct and indirect impact of COVID-19; our ability to develop, obtain regulatory approval for and commercialize current and future product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials; the risk that regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; risks related to the occurrence of adverse safety events; risks related to failure to protect and enforce our intellectual property, and other proprietary rights; risks related to failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions caused by the coronavirus pandemic; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; failure to comply with legal and regulatory requirements; risks relating to access to capital and credit markets; environmental risks; risks relating to the use of social media for our business; and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005385/en/

View post:
Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company's Proprietary Approach to Addressing...

Read More...

What is Genetics? – Life Sciences Articles

Wednesday, July 8th, 2020

Genetics is the study of heredity. Heredity is a biological process whereby a parent passes certain genes onto their children or offspring.

Every child inherits genes from both of their biological parents and these genes, in turn, express specific traits. Some of these traits may be physical for example hair and eye color etc.

On the other hand, some genes may also carry the risk of certain diseases and disorders that may be passed on from parents to their offspring.

Image Credit: fizkes/Shutterstock.com

The genetic information lies within the cell nucleus of each living cell in the body. The information can be considered to be retained in a book for example. Part of this book with the genetic information comes from the father while the other part comes from the mother.

The genes lie within the chromosomes. Humans have 23 pairs of these small thread-like structures in the nucleus of their cells. 23 or half of the total 46 comes from the mother while the other 23 comes from the father.

The chromosomes contain genes just like pages of a book. Some chromosomes may carry thousands of important genes while some may carry only a few.

The chromosomes, and therefore the genes, are made up of the chemical substance called DNA (DeoxyriboNucleic Acid). The chromosomes are very long thin strands of DNA, coiled up tightly.

At one point along their length, each chromosome has a constriction, called the centromere. The centromere divides the chromosomes into two arms: a long arm and a short arm.

Chromosomes are numbered from 1 to 22 and these are common for both sexes and called autosomes. There are also two chromosomes that have been given the letters X and Y and termed sex chromosomes. The X chromosome is much larger than the Y chromosome.

The genes are further made up of unique codes of chemical bases comprising of A, T, C and G (Adenine, Thymine, Cytosine, and Guanine). These chemical bases make up combinations with permutations and combinations. These are akin to the words on a page.

These chemical bases are part of the DNA. The words when strung together act as the blueprints that tell the cells of the body when and how to grow, mature and perform various functions. With age, the genes may be affected and may develop faults and damages due to environmental and endogenous toxins.

Women have 46 chromosomes (44 autosomes plus two copies of the X chromosome) in their body cells. They have half of this or 22 autosomes plus an X chromosome in their egg cells.

Men have 46 chromosomes (44 autosomes plus an X and a Y chromosome) in their body cells and have half of these 22 autosomes plus an X or Y chromosome in their sperm cells.

When the egg joins with the sperm, the resultant baby has 46 chromosomes (with either an XX in a female baby or XY in a male baby).

Each gene is a piece of genetic information. All the DNA in the cell makes up for the human genome. There are about 20,000 genes located on one of the 23 chromosome pairs found in the nucleus.

To date, about 12,800 genes have been mapped to specific locations (loci) on each of the chromosomes. This database was begun as part of the Human Genome Project. The project was officially completed in April 2003 but the exact number of genes in the human genome is still unknown.

Read more:
What is Genetics? - Life Sciences Articles

Read More...

This Company Wants to Rewrite the Future of Genetic DiseaseWithout Crispr Gene Editing – WIRED

Wednesday, July 8th, 2020

That can spell real trouble for the bacteria on the receiving end of this gene shuffle. If those MGEs insert themselves into critical gene regions, its bye-bye bacteria. You can think about MGEs the same way you can think about mutations, says Peters. We wouldnt have evolved without them, but 99.99999 percent of them are bad. Bacteria are trying at any cost to stop MGEs from destabilizing their genome.

The Nobel Prize-winning botanist Barbara McClintock discovered the first known class of MGEs, called transposons, or jumping genes, in maize in 1931. Her technique for staining the plants chromosomes allowed her to see when chunks from one would jump to another. But for many decades, the purpose of all these repeated sections of self-rearranging DNA eluded scientists. Some went so far as to dub the MGE-heavy sections of the human genome junk DNA. It was hard to get funding to study it. But little by little, researchers like Peters discovered that MGEs in bacteria were actually highly-evolved systems for recognizing DNA, writing it, and moving it around. In fact, Crispr itself appears to have evolved from a self-synthesizing transposon, as NIH researchers Eugene Koonin and Kira Makarova described in 2017. (Crispr codes for a protein that cuts specific, recognizable pieces of DNA stored in its genetic memory bank. The transposons allowed Crispr to start amassing that memory bank in the first place.)

Earlier that year, Peters and Koonin published a paper describing how this evolution can sometimes come full circle. They found one type of transposon that had stolen some Crispr genes to help it move between bacterial hosts. They realized that these molecular tools for cutting, copying, and pasting were constantly being shuttled between MGEs, phages, and bacteria to be used alternately as a means of offense or defense. At the end of that paper, Peters and Koonin wrote that these systems could potentially be harnessed for genome-engineering applications.

Not long after, Peters says, he started getting calls from commercial interests. One of them was from Jake Rubens, Tesseras Chief Innovation Officer and co-founder. In 2019, the company began a sponsored research collaboration with Peters Cornell lab around the discovery of new MGEs with genome engineering potential. (Tessera also has other research partnerships, but company officials have not yet disclosed them.)

MGEs come in a few flavors. There are transposons, which can cut themselves out of the genome and hop into a different neighborhood. Retrantransposons make a copy and shuttle that replica to its new home, expanding the size of the genome with each duplication. They both work by having special sequences on either end that define their boundaries. In between are genes for making proteins that recognize those boundaries and either excise them out in the case of transposons, leaving a gap. Or in the case of retrotransposons, copy them, via an RNA-intermediate, into new locations. There are other classes, too, but these are the two that Tessera executives are interested in. Thats because you can add a new string of code between those sequencessay a healthy, non-mutated version of a disease-causing geneand let the MGEs machinery do the work to move that therapeutic DNA into a patients chromosomes.

For the past two years, the companys team of bioinformaticians have been mining public databases that house the genome sequences of hundreds of thousands of bacterial species that scientists have collected from all over the world. In those reams of genetic data, theyve been prospecting for MGEs that might be best suited for making these kinds of therapeutic DNA changes.

So far, company scientists have identified about 6,000 retrotransposons (what Tessera calls RNA writers) and 2,000 transposons (DNA writers) that show potential. Tesseras team of 35 scientists have been conducting experiments in human cells to understand how exactly each one works. Sometimes, a promising, naturally-occurring gene writer will get tweaked further in Tesseras lab, to be more precise or go to a different location. The company hasnt yet demonstrated that any of its gene writers can eliminate an inherited disease. But in mouse models, the team has consistently been able to use them to insert lots of copies of a large green fluorescent protein gene into the animals genomes as a way of proving that they can reliably place designer DNA.

The rest is here:
This Company Wants to Rewrite the Future of Genetic DiseaseWithout Crispr Gene Editing - WIRED

Read More...

Page 14«..10..13141516..2030..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick